within Pharmacolibrary.Drugs.ATC.G;

model G01AF12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fenticonazole is an imidazole antifungal agent used mainly for the treatment of vulvovaginal candidiasis and other superficial fungal infections. It is primarily available as topical and intravaginal formulations and is approved for these uses in some countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic studies in humans reporting specific model parameters for systemic (oral or intravenous) administration of fenticonazole. Most data relate to topical or intravaginal administration, where systemic absorption is considered negligible.</p><h4>References</h4><ol><li><p>Mao, W, et al., &amp; Ding, L (2017). Determination of fenticonazole in human plasma by HPLC-MS/MS and its application to pharmacokinetic studies. <i>Journal of pharmaceutical analysis</i> 7(1) 63–70. DOI:<a href=&quot;https://doi.org/10.1016/j.jpha.2016.09.002&quot;>10.1016/j.jpha.2016.09.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29404019/&quot;>https://pubmed.ncbi.nlm.nih.gov/29404019</a></p></li><li><p>Campos, R, et al., &amp; De Nucci, G (2018). The rabbit vagina as an in vivo model for vaginal fenticonazole permeability and toxicity. <i>Journal of pharmacological and toxicological methods</i> 94(Pt 1) 14–18. DOI:<a href=&quot;https://doi.org/10.1016/j.vascn.2018.04.001&quot;>10.1016/j.vascn.2018.04.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29630936/&quot;>https://pubmed.ncbi.nlm.nih.gov/29630936</a></p></li><li><p>Novelli, A, et al., &amp; Periti, P (1991). Systemic absorption of 3H-fenticonazole after vaginal administration of 1 gram in patients. <i>Journal of chemotherapy (Florence, Italy)</i> 3(1) 23–27. DOI:<a href=&quot;https://doi.org/10.1080/1120009x.1991.11739058&quot;>10.1080/1120009x.1991.11739058</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2019858/&quot;>https://pubmed.ncbi.nlm.nih.gov/2019858</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G01AF12;
